Systems and methods for ultrasound induced thrombolysis with magnetic microbubbles, optional nanodroplets, and a rotational magnetic field
The disclosure provides systems for ultrasound-induced thrombolysis with magnetic microbubbles under a rotational/alternating magnetic field, sonothrombolysis systems with magnetic microbubbles and optional nanodroplets for inducing thrombolysis under an acoustic field, and a rotational/alternating magnetic field, and methods of treating patients with blood clots using the sonothrombolysis systems of the present disclosure.
1. A system comprising:
a plurality of magnetic microbubbles (MMBs) having a gas core and a layer of superparamagnetic nanoparticles around the gas core,
an ultrasound transducer effective to induce cavitation of the MMBs, wherein the ultrasound transducer is configured to generate an acoustic frequency of about 100 kHz to about 5 MHz, with an ultrasound duty cycle of about 0.5% to about 25%, and an input voltage of about 10V pp to 250 V pp , and
a rotational magnetic field generator effective to accumulate MMBs in a target region and increase cavitation of the MMBs induced by the ultrasound transducer.
2. The system of claim 1 , wherein the system is a sonothrombolysis system and the ultrasound transducer and the rotational magnetic field generator are adapted for placement near a target clot region of a patient, and further comprising a catheter configured for in vivo intravascular delivery of the MMBs to the target clot region of the patient, wherein the rotational magnetic field generator is effective to accumulate the MMBs in the target clot region and increase cavitation of the MMBs induced by the ultrasound transducer, such that cavitating MMBs are effective to induce partial or complete thrombolysis of a blood clot in the target clot region.
3. The system of claim 1 , further comprising a plurality of nanodroplets (NDs).
4. The system of claim 3 , wherein the system is a sonothrombolysis system and further comprises a catheter configured for in vivo intravascular delivery of the MMBs and the NDs to the target clot region of a patient.
5. The system of claim 3 , wherein the NDs comprise:
a liquid core comprising one or more materials selected from the group consisting of: decafluorobutane (DFB) (C 4 F 10 ), perfluorohexane (PFH) (C 6 F 14 ), octafluoropropane (OFP) (C 3 F 8 ), perfluoropentane (PFP) (C 5 F 12 ), mesoporous silica nanoparticles (MSNs), magnetic nanodroplets (MNDs); and
an outer shell comprising one or more materials from the group consisting of: oil, polymers, surfactants, lipids, albumin, fluorosurfactant (Zonyl FSO), MSPC, DSPC, DPPC, DSPG, DSPE-PEG-2000, DSPE-PEG-5000, cholesterol, and 1,2-distearoyl-sn-glycero-3-phosphocholine,
wherein the NDs have an average diameter of about 150 nm-350 nm.
6. The system of claim 1 , wherein the ultrasound transducer is selected from: an external HIFU transducer or an intravascular ultrasound (IVUS) transducer.
7. The system of claim 6 , wherein the IVUS transducer is a forward-looking stacked IVUS transducer.
8. The system of claim 7 , wherein the IVUS transducer comprises three or more stacked piezoelectric plates having alternating poling directions.
9. The system of claim 1 , wherein the superparamagnetic nanoparticles in the MMBs comprise iron oxide superparamagnetic nanoparticles having an average size of 10-100 nm.
10. The system of claim 9 , wherein the MMBs comprise a surface coating around the layer of superparamagnetic nanoparticles, the surface coating comprising a material selected from the group consisting of oils, polymers, surfactants, lipids, albumin, fluorosurfactant (Zonyl FSO), MSPC, DSPC, DPPC, DSPG, DSPE-PEG-2000, DSPE-PEG-5000, cholesterol, 1,2-distearoyl-sn-glycero-3-phosphocholine, and combinations thereof.
11. The system of claim 1 , wherein the MMBs have an average diameter of about 1 μm to 100 μm.
12. The system of claim 1 , wherein the rotational magnetic field generator includes a cylindrical permanent magnet coupled to a power source to rotate the magnet cylinder.
13. A method of treating blood clots, the method comprising:
administering magnetic microbubbles (MMBs) intravascularly to a patient in need of treatment for a blood clot in a blood vessel, the MMBs having a gas core and a layer of superparamagnetic nanoparticles around the gas core;
localizing the MMBs to a target clot region in the blood vessel by application of a magnetic field;
generating a rotational magnetic field in the target clot region to retain the MMBs in the target clot region and enhance ultrasound-induced movement of the MMBs; and
using an ultrasound transducer to acoustically activate the MMBs to generate movement of the MMBs within the blood vessel in the target clot region, wherein the ultrasound transducer generates an acoustic frequency of about 100 kHz to about 5 MHz, has an ultrasound duty cycle of about 0.5% to about 25%, and has an input voltage of about 10 V pp to 250 V pp , and wherein movement of the MMBs induced by the ultrasound is increased under the rotational magnetic field, such that the movement of the MMBs is effective to reduce the blood clot in size.
14. The method of claim 13 , wherein the ultrasound-induced movement is selected from the group consisting of: cavitation of the MMBs, microstreaming, and combinations thereof.
15. The method of claim 13 , further comprising administering a plurality of nanodroplets (NDs) to the patient with the MMBs.
16. The method of claim 15 , wherein the concentration of NDs administered is about 10 8 -10 12 NDs/mL.
17. The method of claim 15 , wherein the concentration ratio of NDs/MMBs is from about 10:1 to 1:10.
18. The method of claim 13 , wherein the ultrasound transducer is selected from the group consisting of: an external HIFU transducer and an intravascular ultrasound (IVUS) transducer.
19. The method of claim 13 , wherein the MMBs are iron oxide MMBs having an average diameter of about 1 μm to 100 μm.
20. The method of claim 13 , wherein acoustic activation of the MMBs under the rotational magnetic field increases a lysis rate of the blood clot as compared to acoustic activation of non-magnetic microbubbles with an ultrasound transducer alone.
21. The method of claim 13 , wherein the concentration of MMBs administered is about 10 7 -10 12 MMBs/mL.
22. The method of claim 13 , wherein the rotational magnetic field has a magnetic frequency of about 1 Hz to about 300 Hz and a magnetic flux density of about 1 mT to 80 mT.
23. A kit comprising:
an ultrasound transducer effective to induce in vivo cavitation of a plurality of magnetic microbubbles (MMBs) in a target region of a subject,
a portable, targeted rotational magnetic field generator effective to accumulate MMBs in a target region and increase cavitation of the MMBs induced by the ultrasound transducer, and
instructions for using the ultrasound transducer and portable, targeted rotational magnetic field generator with a composition of MMBs and optional NDs to treat a subject, wherein the instructions describe the use of the ultrasound transducer to generate an acoustic frequency of about 100 kHz to about 5 MHz, with an ultrasound duty cycle of about 0.5% to about 25%, and an input voltage of about 10 V pp to 250 V pp .
24. The kit of claim 23 , wherein the kit further includes nanodroplets (NDs), and wherein the ultrasound transducer is an intravascular ultrasound (IVUS) transducer that is integrated into a catheter, the catheter further comprising an integrated delivery lumen for administration of a composition comprising MMBs to the target region of the subject, and wherein the instructions describe the use of the IVUS transducer, the portable, targeted rotational magnetic field generator and composition of MMBs and NDs for intravascular sonothrombolysis of a blood clot in a subject.